Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

High-dose melphalan 200 mg/m(2) (MEL 200) is the standard of care as a conditioning regimen for autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma (MM). We compared a novel conditioning combination incorporating busulfan, melphalan, and bortezomib (BUMELVEL) versus stand...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Tulio E., Hari, Parameswaran, Stiff, Patrick J., Smith, Scott E., Sterrenberg, Danielle, Vesole, David H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075527/
https://www.ncbi.nlm.nih.gov/pubmed/27164062
http://dx.doi.org/10.1016/j.bbmt.2016.03.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075527/
https://www.ncbi.nlm.nih.gov/pubmed/27164062
http://dx.doi.org/10.1016/j.bbmt.2016.03.021

Ejemplares similares